Search results
Order by most recent / most popular / relevance
Results: 1-8 of 8
Malaria combination patent invalidated for obviousness
- McDermott Will & Emery
- -
- United Kingdom
- -
- March 13 2013
In Glenmark Generics (Europe) Limited & others v The Wellcome Foundation Limited & Glaxo Group Ltd 2013 EWHC 148 (Pat) the High Court has held that
Court of Appeal upholds invalidity of Alzheimer’s drug patent
- McDermott Will & Emery
- -
- United Kingdom
- -
- January 9 2013
In Novartis AG v Generics (UK) Ltd (trading as Mylan) 2012 EWCA Civ 1623, the Court of Appeal has upheld the decision of the High Court that a patent
High Court of England and Wales has jurisdiction to try pan-European declaration of non-infringement action
- McDermott Will & Emery
- -
- European Union, United Kingdom
- -
- January 9 2013
In Actavis Group HF v Eli Lilly and Company 2012 EWHC 3316 (Pat) the High Court of England and Wales has held that, in cases where there is no challenge
Court of Appeal of England and Wales re-examination of Neutrokine-a patent establishes validity of claims
- McDermott Will & Emery
- -
- United Kingdom
- -
- November 7 2012
Following the decision of the Supreme Court of England and Wales that Human Genome Sciences Inc’s (HGS) patent for Neutrokine-α was not invalid for lack of industrial applicability, the Court of Appeal has decided the remaining validity issues in relation to three claims
Multiple sclerosis drug patent survives lack of technical contribution and ambiguity attacks
- McDermott Will & Emery
- -
- United Kingdom
- -
- August 8 2012
After a 13 day trial, featuring 11 expert witnesses, the validity of Yeda’s glatiramer acetate patent has been upheld by Mr Justice Arnold in Generics (ta Mylan) v Yeda and Teva 2012 EWHC 1848 (Pat
UK Supreme Court steps into line with Europe, but rejects U.S. approach
- McDermott Will & Emery
- -
- European Union, United Kingdom, USA
- -
- November 30 2011
The UK’s highest court recently considered the provisions of the European Patent Convention (EPC) centering on the “susceptible of industrial application” requirement in the context of a patent describing a DNA sequence for a new protein, Neutrokine-α, which was a member of a group of similar proteins known as the TNF ligand superfamily
Ranbaxy v AstraZeneca: skilled persons
- McDermott Will & Emery
- -
- United Kingdom
- -
- September 28 2011
In Ranbaxy v AstraZeneca 2011 EWHC 1831 (Pat), Ranbaxy was granted a declaration for non-infringement with respect to AstraZeneca’s patent relating to magnesium esomeprazole
Occlutech GmbH v AGA Medical Corp: claim construction
- McDermott Will & Emery
- -
- United Kingdom
- -
- September 28 2010
Dismissing an appeal from a decision of Mr Justice Mann, the Court of Appeal, in Occlutech GmbH v AGA Medical Corp 2010 EWCA (Civ) 702, has decided that, although in a suitable context the word "clamp" could be understood to carry an extended meaning, in the context of the patent in suit, a "clamp" meant a "clamp" in the everyday sense of the word, and not an all-inclusive term for means of securing things together
Current Search
- Workarea - Healthcare
- Workarea - Patents
- Firm Name - McDermott Will & Emery
- Jurisdiction - United Kingdom